•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
In the news release, Vanguard Expands High-Yield Offering with Vanguard U.S. High-Yield Corporate Bond Index ETF, issued 04-Jun-2026 by Vanguard over PR Newswire, we...
TAIPEI, June 5, 2026 /PRNewswire/ -- COMPUTEX 2026, one of the world's leading exhibitions for AIoT and startup innovation, concluded successfully today. Under the...
NEW YORK, June 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") conducted a consultation with market participants on potential changes to the S&P U.S....
NEW YORK, June 4, 2026 /PRNewswire/ -- In response to shifting demand across professional and everyday settings, Better Business Advice has recognized Quay for its...
The Forums will equip business and technology leaders with the frameworks and insights needed to scale AI and deliver measurable outcomesSINGAPORE, June 4, 2026...